The target of ATH434 is labile iron as has been told by Stamler and as Dr. Kosman has demonstrated in his ATH434 paper. Now it looks like ATH434 would also be perfect to be used in thalassemia patients to prevent cardiac problems. Cooperation with thalassemia teams would be needed to demonstrate if ATH434 will take the plasma iron down.Labile plasma iron and echocardiographic parameters are associated to cardiac events in β-thalassemic patients
AffiliationsDOI: 10.1111/eci.13954
- PMID: 36645727
Abstract
Background and aim: Notwithstanding the improvement in therapies, patients affected by thalassemia major (TM) and intermedia (TI) are still at high risk of cardiac complications. This study aimed at evaluating the incidence and predictive factors for developing cardiac events in adult β-TM and TI patients.
Population and methods: Data on diagnosis and clinical history were collected retrospectively; prospective data on new-onset cardiac failure and arrhythmias, echocardiographic parameters, biochemical variables including non-transferrin-bound iron (NTBI) and labile plasma iron (LPI), magnetic resonance imaging (MRI) T2* measurement of hepatic and cardiac iron deposits, and iron chelation therapy were recorded during a 6 year follow-up.
Results: Thirty-seven patients, 29 TM and 8 TI, were included. At baseline, 8 TM patients and 1 TI patient had previously experienced a cardiac event (mainly heart failure). All patients were on chelation therapy and only 3 TM patients had mild-to-severe cardiac siderosis. During follow-up, 11 patients (29.7%) experienced a new cardiac event. The occurrence of cardiac events was correlated to high LPI levels (OR 12.0, 95% CI 1.56-92.3, p 0.017), low mean pre-transfusion hemoglobin (OR 0.21, 95% C.I. 0.051-0.761, p 0.21), and echocardiographic parameters suggestive of myocardial hypertrophy. Multivariate analysis disclosed high LPI and left ventricle mass index (LVMI) as independent variables significantly associated with cardiac events. Cardiac iron deposits measured by MRI T2* failed to predict cardiac events.
Conclusion: LPI, Hb levels, and echocardiographic parameters assessing cardiac remodeling are associated to cardiac events in adult TM and TI patients. LPI might represent both a prognostic marker and a potential target for novel treatment strategies. Further studies are war ranted to confirm our findings on larger populations.
- Forums
- ASX - By Stock
- Labile iron also a problem of thalassemia patients
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
1.1¢

The target of ATH434 is labile iron as has been told by Stamler...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $46.86K | 4.283M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
64 | 25268416 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 18128695 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
63 | 25148416 | 0.010 |
22 | 11669721 | 0.009 |
17 | 6584122 | 0.008 |
4 | 1380001 | 0.007 |
8 | 3400001 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 18128695 | 9 |
0.012 | 3480098 | 13 |
0.013 | 4872337 | 18 |
0.014 | 18433645 | 12 |
0.015 | 22174547 | 15 |
Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |